DAWN
Day One Biopharmaceuticals is a biopharma company focused on developing targeted cancer therapies for patients of all ages, with an emphasis on pediatric and adult cancers. The company emphasizes a research-driven approach to disrupt traditional drug development and bring new medicines to children and adults with cancer. Its science profile includes programs like OJEMDA (tovorafenib) and a pipeline spanning pediatric neuro-oncology and broader oncology indications, supported by clinical trials and investigator-sponsored research. Headquartered in the United States, Day One positions itself around urgency and patient-centric development in oncology.